October 25, 2021
MSD said on October 22 that it has filed its PD-1 inhibitor Keytruda (pembrolizumab) for an additional indication of advanced/relapsed cervical cancer in Japan. The submission rides on the back of data from the global PIII KEYNOTE-826 study, which investigated...read more